ProPhase Labs (NASDAQ:PRPH) and Merus (NASDAQ:MRUS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.
This is a breakdown of current recommendations for ProPhase Labs and Merus, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Merus has a consensus price target of $34.00, suggesting a potential upside of 115.19%. Given Merus’ higher probable upside, analysts plainly believe Merus is more favorable than ProPhase Labs.
Institutional & Insider Ownership
4.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 53.3% of Merus shares are held by institutional investors. 29.2% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares ProPhase Labs and Merus’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ProPhase Labs||$9.87 million||3.53||$40.58 million||N/A||N/A|
|Merus||$15.36 million||23.40||-$82.61 million||($4.29)||-3.68|
ProPhase Labs has higher earnings, but lower revenue than Merus.
This table compares ProPhase Labs and Merus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
ProPhase Labs has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Merus has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500.
Merus beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.
ProPhase Labs Company Profile
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health. In addition, the company provides contract manufacturing services of OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.